VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
VolitionRx signed a non-binding Letter of Intent with Denmark's Missionpharma A/S to explore development and worldwide launch of Volition's lateral flow prototype test for NETosis. The initial clinical focus is a finger-prick test for triaging neonatal sepsis in newborns and young infants, targeting low- and middle-income countries where sepsis is a major cause of newborn deaths. Missionpharma, which supplies UN agencies and health ministries and reaches over 100 million patients annually, could assist with low-cost manufacturing, clinical studies, and distribution.
Key figures
- Note
- LOI is non-binding; no financial terms disclosed
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.